J&J Pops on Decision to Split Consumer Health Business
By Dhirendra Tripathi Investing.com – Johnson & Johnson (NYSE:JNJ) stock jumped more than 5% in Friday’s trading as the company revealed its plan to split its consumer health business into a...
Strong Buy
or
Eli Lilly News & Analysis
-
-
Eli Lilly - Boehringer Ingelheim granted FDA’s priority review for heart failure drug
Eli Lilly (LLY) and Boehringer Ingelheim announced that the FDA has accepted a supplemental New Drug Application ((sNDA)) for the heart failure drug Jardiance under priority...
-
PPH Pertinent as Some Cheap Pharma Stocks Offer Big Dividend Growth
Healthcare stocks are solid but not spectacular performers. For example, the S&P 500 Health Care Index is higher by more than 17%, though that lags the broader market. Speaking of lagging,...
-
Regeneron, Eli Lilly join selloff as Pfizer hopes for a COVID-19 pill
Established makers of COVID-19 antibody treatments Vir Biotechnology , Regeneron , and Eli Lilly have become the latest additions to a selloff driven by positive...
-
Eli Lilly pulls rolling submission seeking EU nod for COVID-19 therapy
Eli Lilly (LLY) has withdrawn from a real-time review conducted by the European Medicines Agency ((EMA)) for bamlanivimab and etesevimab, a combination of monoclonal antibodies...
-
Eli Lilly gets additional U.S. government order for bamlanivimab/etesevimab combo
Eli Lilly (LLY) announces an additional purchase by the U.S. government for bamlanivimab with etesevimab for administration together in the treatment of mild to moderate...
-
Eli Lilly’s Q3 Earnings Miss but Revenues Beat Estimates
American pharmaceutical company Eli Lilly and Company (LLY) has posted lower-than-expected earnings for the third quarter of 2021. However, revenues surpassed analysts’ expectations on the...
-
Dow Futures Rise 125 Pts; Facebook 3Q in Focus
By Peter Nurse Investing.com - U.S. stocks are seen opening higher Tuesday, carrying on the recent positive tone ahead of the release of a slew of corporate earnings, particularly from...
-
Eli Lilly Earnings miss, Revenue beats In Q3
Investing.com - Eli Lilly (NYSE:LLY) reported on Tuesday third quarter {{erl-273||earnings that missed analysts' forecasts and revenue that topped expectations. Eli Lilly announced...
-
Marketmind: Trillion-dollar Tesla
LONDON (Reuters) - A look at the day ahead from Sujata Rao Apple (NASDAQ:AAPL), Amazon (NASDAQ:AMZN), Microsoft (NASDAQ:MSFT), Alphabet (NASDAQ:GOOGL)... and Tesla (NASDAQ:TSLA). We now...
-
Eli Lilly Q3 2021 Earnings Preview
Eli Lilly (NYSE:LLY) is scheduled to announce Q3 earnings results on Tuesday, October 26th, before market open.The consensus EPS Estimate is $1.96 (+27.3% Y/Y) and the consensus...
-
Market Snapshot: The Federal Reserve’s next interest rate-hike cycle is coming but may not look like what officials have been projecting
Traders are pricing in a more aggressive start to the Fed's approaching campaign of interest-rate increases and, in some cases, an early end to it too.
-
-
Eli Lilly highlights results from tirzepatide diabetes study
Eli Lilly (LLY) highlighted results from the company's study of tirzepatide compared to insulin glargine in adults with type 2 diabetes, published in The Lancet.Tirzepatide is a...
-
Eli Lilly declares $0.85 dividend
Eli Lilly (NYSE:LLY) declares $0.85/share quarterly dividend, in line with previous.Forward yield 1.43%Payable Dec. 10; for shareholders of record Nov. 15; ex-div Nov.
-
Monday’s Top Analyst Upgrades and Downgrades: Carvana, Cloudflare, Conoco, Exxon, Eli Lilly, SoFi, Starbucks and More
Monday's top analyst upgrades and downgrades included Carvana, Cloudflare, Comcast, ConocoPhillips, Constellation Brands, Exxon Mobil, Eli Lilly, SoFi Technologies and Starbucks.
-
Eli Lilly, AbbVie favorites at JP Morgan as big pharma set for Q3 earnings
Despite further upside expected for Merck (MRK) on account of its much-anticipated COVID-19 pill, the analysts at J.P
-
GLP-1 Receptor Agonist Market to Surpass US$ 19,253.8 Million by 2028, Says Coherent Market Insights (CMI)
SEATTLE, Oct. 06, 2021 (GLOBE NEWSWIRE) -- According to Coherent Market Insights' analysis, the global GLP-1 receptor agonist market is estimated to be valued at US$ 12,720.6 million in...
-
Extremely Robust Esophageal Cancer Pipeline Expected to Change the Pace of Cancer Treatment as Many Critical Pharma Companies are Proactively Participating in Developing Novel Therapies Estimates DelveInsight
Las Vegas, USA, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Extremely Robust Esophageal Cancer Pipeline Expected to Change the Pace of Cancer Treatment as Many Critical Pharma Companies are...
-
Bringing Mental Health Pharmacology into the 21st Century: How the Marriage of Enveric Biosciences and MagicMed Industries Could Revolutionize the Way We Treat Mental Health
Photo by Christina Victoria Craft on Unsplash The world is finally waking up to the importance of mental health. It is becoming more acceptable to talk about mental illness. Celebrities and...
-
Eli Lilly CEO pushes back against proposed Medicare drug negotiation plan
David Ricks, CEO of Eli Lilly (LLY), spoke out against a proposed bill that would allow Medicare to negotiate drug prices, saying that it would force a radical reduction in R&D...
-
Eli Lilly’s recalled products came from Indiana plant already cited for quality issues - Reuters
A recently recalled batch of Glucagon manufactured by Eli Lilly (LLY) came from one of the company’s production facilities, which was already under the investigation of the FDA for...
-
: Location, location, location: Ohio is benefiting in tech growth as a major transportation hub
Amazon.com Inc., Google parent Alphabet Inc., and Facebook are making billion-dollar investments in and around Cincinnati and central Ohio to take advantage of airport, data centers, and a...
-
: Why a pill you take at home could change the direction of the pandemic
Merck and Ridgeback Therapeutics Inc.'s promising oral antiviral could shift the direction of the pandemic by making it easier for people with COVID-19 to take a pill at home that can keep...
-
Eli Lilly's Mirikizumab Maintains Symptomatic Remission for Two Years In Ulcerative Colitis Patients
Eli Lilly And Co (NYSE: LLY) has posted new data from the Phase 2 study of mirikizumab in moderately to severely active ulcerative colitis (UC) patients. Related: Eli Lilly's Mirikizumab...
-
Eli Lilly Shares Positive Tirzepatide Data At EASD Annual Meeting
Eli Lilly And Co (NYSE: LLY) posted data from the SURPASS-3 CGM sub-study of tirzepatide in a subpopulation of 243 participants who wore continuous glucose monitoring (CGM) for 7 to 10 days...
-
U.S. shares mixed at close of trade; Dow Jones Industrial Average up 0.26%
Investing.com – U.S. equities were mixed at the close on Wednesday, as gains in the Utilities, Healthcare and Consumer Goods sectors propelled shares higher while losses in the Basic...
-
Stocks making the biggest moves midday: Dollar Tree, Gap, Affirm, Micron, Netflix and more
These are the stocks posting the largest moves in midday trading.
-
Eli Lilly gains as Citi upgrades to buy on recent weakness
Eli Lilly has recorded the biggest one-day gain since early August after Citigroup upgraded the stock to buy from neutral, noting the valuation disconnect of...
-
Wednesday’s Top Analyst Upgrades and Downgrades: Boeing, Conagra, Eli Lilly, Hess, HP, Lockheed Martin, Nike and More
Wednesday's top analyst upgrades and downgrades included Boeing, Conagra Brands, Constellation Brands, Eli Lilly, Hess, HP, Lockheed Martin, Nike, Occidental Petroleum and Wingstop.
-
Stocks making the biggest moves premarket: Micron, Eli Lilly, Netflix, Lucid and more
These are the stocks posting the largest moves before the bell.
-
Eli Lilly to reduce list price of Insulin Lispro Injection
Eli Lilly (LLY) announces its decision to lower the list price of Insulin Lispro Injection in the U.S. by 40%, with effect from Jan
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
